These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 16288390

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
    Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A, Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group.
    Clin Infect Dis; 2002 Apr 15; 34(8):1076-83. PubMed ID: 11914996
    [Abstract] [Full Text] [Related]

  • 8. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar 15; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 9. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B, DRAGON Study Team.
    Int J Antimicrob Agents; 2009 Nov 15; 34(5):439-45. PubMed ID: 19692210
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
    Paladino JA, Eubanks DA, Adelman MH, Schentag JJ.
    J Am Geriatr Soc; 2007 May 15; 55(5):651-7. PubMed ID: 17493183
    [Abstract] [Full Text] [Related]

  • 12. Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
    Ewig S, Hecker H, Suttorp N, Marre R, Welte T, CAPNETZ study group.
    J Infect; 2011 Mar 15; 62(3):218-25. PubMed ID: 21276814
    [Abstract] [Full Text] [Related]

  • 13. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM, Tenías JM, Querol-Borrás JM, Labrador T, Nieto A, González-Granda D, Martínez I.
    Int J Antimicrob Agents; 2005 Jan 15; 25(1):75-83. PubMed ID: 15620830
    [Abstract] [Full Text] [Related]

  • 14. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.
    Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ.
    Arch Intern Med; 1995 Jun 26; 155(12):1273-6. PubMed ID: 7778957
    [Abstract] [Full Text] [Related]

  • 15. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
    Finch R, Schürmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo JL, Nikolaides P, Ogundare F, Raz R, Zuck P, Hoeffken G.
    Antimicrob Agents Chemother; 2002 Jun 26; 46(6):1746-54. PubMed ID: 12019085
    [Abstract] [Full Text] [Related]

  • 16. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R, Martínez MA, Rubilar L, Payá E, Quevedo I, Puppo H, Girardi G, Castro-Rodriguez JA.
    Pediatr Pulmonol; 2003 Feb 26; 35(2):91-8. PubMed ID: 12526069
    [Abstract] [Full Text] [Related]

  • 17. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods GL, Friedland I.
    J Antimicrob Chemother; 2004 Jun 26; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [Abstract] [Full Text] [Related]

  • 18. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.
    Davis SL, Delgado G, McKinnon PS.
    Clin Infect Dis; 2005 Jul 15; 41 Suppl 2():S136-43. PubMed ID: 15942880
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A, Holman A, Evers T.
    Curr Med Res Opin; 2008 May 15; 24(5):1279-84. PubMed ID: 18358083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.